Signal transduction modulators for cancer therapy: from promise to practice?
Lobbezoo
Marinus W
MW
NDDO Research Foundation, Amsterdam, The Netherlands. lobbezoo@euronet.nl
Giaccone
Giuseppe
G
Van Kalken
Coenraad
C
D000970:Antineoplastic Agents / Q000592:standards / Q000627:therapeutic use; D002986:Clinical Trials as Topic; D004791:Enzyme Inhibitors / Q000592:standards / Q000627:therapeutic use; D066246:ErbB Receptors / Q000187:drug effects; D000077156:Gefitinib; D007722:Health Knowledge, Attitudes, Practice; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy* / Q000503:physiopathology*; D011799:Quinazolines / Q000592:standards / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects* / Q000502:physiology*; D014481:United States; D040301:Vascular Endothelial Growth Factor Receptor-2 / Q000187:drug effects
D000970:Antineoplastic Agents; D004791:Enzyme Inhibitors; D011799:Quinazolines; D066246:ErbB Receptors; D040301:Vascular Endothelial Growth Factor Receptor-2; D000077156:Gefitinib